Table 5

Epimerase activitya in ovarian cancer cases and controls by potential confounding variables

CasesControls
nMean(SE)nMean(SE)
All48720.32(0.31)38121.64(0.36)b
Age
<5023220.32(0.47)19020.80(0.49)
>5025520.31(0.42)19122.47(0.51)b
Study center
MA38619.43(0.33)31020.79(0.38)b
NH10123.70(0.72)7125.35(0.77)
Religion
Jewish4821.27(0.97)3020.90(1.45)
Non-Jewish43920.21(0.33)35121.70(0.36)b
BMI
<205620.09(0.98)4121.16(1.05)
20–2418120.46(0.50)14921.28(0.59)
>2425020.26(0.44)19021.97(0.49)b
Parity
016119.66(0.57)8221.23(0.79)
≥132620.64(0.37)29921.75(0.40)b
Sample processing interval
<1 day23321.45(0.41)17723.17(0.44)b
≥1 day17016.95(0.47)13517.61(0.56)
Year of analysis
1992–199310117.68(0.60)8720.40(0.66)b
199412918.47(0.59)9019.44(0.80)
199512721.73(0.58)9522.45(0.69)
19964620.68(0.83)4020.55(0.88)
Histological type
Serous borderline7119.67(0.83)38121.64(0.36)b
Serous invasive19920.12(0.48)38121.64(0.36)b
Mucinous7320.82(0.80)38121.64(0.36)
Endometrioid/Clear cell11020.27(0.68)38121.64(0.36)b
Other/Undifferentiated3421.86(1.25)38121.64(0.36)
  • a Units of activity are micromoles of hexose conversion/h/g hemoglobin.

  • b P ≤ 0.05.